Issue #3 2016 – Digital edition

30 June 2016  •  Author(s): European Pharmaceutical Review

In the digital version of Issue #3 2016:

  • European Pharmaceutical Review Issue 3 2016FOREWORD – Biosimilars: future prospects
    David P. Elder, JPAG chair and Consultant
  • REGULATORY INSIGHT: Pharma sector – long a target for antitrust enforcers
    Diarmuid Ryan and Martin Rees, Squire Patton Boggs
    With articles from Martin Sawer, Healthcare Distribution Association, Maarten Van Baelen and Johan Verhaeghe, Medicines for Europe and Micael Lopes and Michael A. Graf, Deloitte Consulting
  • MICROFLUIDICS: Microfluidics in cell-to-cell signalling measurements
    Laura D. Casto and Christopher A. Baker, University of Tennessee
    With articles from David Elder and Paul Newby, GlaxoSmithKline and Tim Sandle, Bio Products Laboratory. Plus a microbiology roundtable
  • PAT SERIES: Recent achievements in NIR-based on-line monitoring of lyophilisation processes
    Adrian Funke, Bayer Pharma AG, Reinhard Gross, Stephan Tosch and Albert Tulke, Bayer Technology GmbH
  • ANTIBIOTIC RESISTANCE: Interview with Bjorn Herpers, Micreos

The rest of this content is restricted to logged-in subscribers. Login or register (it's free!) to view the full content.

3 responses to “Issue #3 2016 – Digital edition”

  1. Vijayeendra Katageri says:

    Good coverage and contents of Bio similars, welcome.

  2. Tatyana says:

    I am from Russia. I work at Servier.

  3. menelaos fountas says:


Leave a reply


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...